These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20025594)

  • 1. Mouse models of autoimmune diseases.
    Marques A; Müller S
    Curr Drug Discov Technol; 2009 Dec; 6(4):262-9. PubMed ID: 20025594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.
    Jenh CH; Cox MA; Cui L; Reich EP; Sullivan L; Chen SC; Kinsley D; Qian S; Kim SH; Rosenblum S; Kozlowski J; Fine JS; Zavodny PJ; Lundell D
    BMC Immunol; 2012 Jan; 13():2. PubMed ID: 22233170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs of abuse and experimental autoimmune diseases.
    Lyman WD
    Adv Exp Med Biol; 1991; 288():81-92. PubMed ID: 1659140
    [No Abstract]   [Full Text] [Related]  

  • 4. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.
    Lange F; Bajtner E; Rintisch C; Nandakumar KS; Sack U; Holmdahl R
    Ann Rheum Dis; 2005 Apr; 64(4):599-605. PubMed ID: 15345503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic risk factors for autoimmune diseases.
    Feltkamp TE; Aarden LA; Lucas CJ; Verweij CL; de Vries RR
    Immunol Today; 1999 Jan; 20(1):10-2. PubMed ID: 10081223
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for common autoimmune disease genes controlling onset, severity, and chronicity based on experimental models for multiple sclerosis and rheumatoid arthritis.
    Bergsteinsdottir K; Yang HT; Pettersson U; Holmdahl R
    J Immunol; 2000 Feb; 164(3):1564-8. PubMed ID: 10640775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models.
    Leung PS; Shu SA; Kenny TP; Wu PY; Tao MH
    Autoimmun Rev; 2010 Mar; 9(5):A400-5. PubMed ID: 20035901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics of susceptibility to chronic experimental encephalomyelitis and arthritis.
    Holmdahl R
    Curr Opin Immunol; 1998 Dec; 10(6):710-7. PubMed ID: 9914217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno- and genetic therapy in autoimmune diseases.
    Chernajovsky Y; Dreja H; Daly G; Annenkov A; Gould D; Adams G; Croxford JL; Baker D; Podhajcer OL; Mageed RA
    Genes Immun; 2000 Jun; 1(5):295-307. PubMed ID: 11196690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?
    Farooqi N; Gran B; Constantinescu CS
    J Neurochem; 2010 Nov; 115(4):829-44. PubMed ID: 20807309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping and identification of autoimmunity genes.
    Encinas JA; Kuchroo VK
    Curr Opin Immunol; 2000 Dec; 12(6):691-7. PubMed ID: 11102774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aire is not essential for regulating neuroinflammatory disease in mice transgenic for human autoimmune-diseases associated MHC class II genes HLA-DR2b and HLA-DR4.
    Nalawade SA; Ji N; Raphael I; Pratt A; Kraig E; Forsthuber TG
    Cell Immunol; 2018 Sep; 331():38-48. PubMed ID: 29789121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders.
    Hultqvist M; Nandakumar KS; Björklund U; Holmdahl R
    Ann Rheum Dis; 2009 Jan; 68(1):130-5. PubMed ID: 18347009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copolymer 1 from the laboratory to FDA.
    Teitelbaum D; Sela M; Arnon R
    Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating the validity of animal models for research into therapies for immune-based disorders.
    't Hart BA; Amor S; Jonker M
    Drug Discov Today; 2004 Jun; 9(12):517-24. PubMed ID: 15183159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular aspects of HLA class II and some autoimmune diseases.
    Lepage V; Lamm LU; Charron D
    Eur J Immunogenet; 1993 Jun; 20(3):153-64. PubMed ID: 8338813
    [No Abstract]   [Full Text] [Related]  

  • 17. Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid.
    Eidinoff H
    Med Hypotheses; 1988 Apr; 25(4):219-22. PubMed ID: 2452965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
    Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
    Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models: Not close enough.
    Rice J
    Nature; 2012 Apr; 484(7393):S9. PubMed ID: 22509510
    [No Abstract]   [Full Text] [Related]  

  • 20. Who believes in "communication"? The Norman Cousins Lecture, 1999.
    Heijnen CJ
    Brain Behav Immun; 2000 Mar; 14(1):2-9. PubMed ID: 10729213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.